Defining response in migraine: Which endpoints are important?

European Neurology

Volumn 53, Issue 1 SUPPL., 2005, Pages 22-28

  Edmeads, John ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Almotriptan; Migraine; Sustained pain free; Tolerability; Triptan

Indexed keywords

ALMOTRIPTAN; CIMETIDINE; CLARITHROMYCIN; ELETRIPTAN; FROVATRIPTAN; ITRACONAZOLE; KETOCONAZOLE; MONOAMINE OXIDASE INHIBITOR; NARATRIPTAN; NEFAZODONE; NELFINAVIR; PLACEBO; RITONAVIR; RIZATRIPTAN; SUMATRIPTAN; TROLEANDOMYCIN; ZOLMITRIPTAN;

ANALGESIA; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFERENCE PAPER; DATA ANALYSIS; DISEASE SEVERITY; DOSE RESPONSE; DROWSINESS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SCREENING; DRUG TOLERABILITY; EXPECTATION; HEADACHE; HUMAN; META ANALYSIS; MIGRAINE; OUTCOMES RESEARCH; PAIN ASSESSMENT; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT DISEASE; RESPONSE TIME; SIDE EFFECT; SYMPTOM; TIME;

HUMANS; META-ANALYSIS; MIGRAINE DISORDERS; RANDOMIZED CONTROLLED TRIALS; SEROTONIN AGONISTS; TREATMENT OUTCOME;

EID: 20444446295     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000085038     Document Type: Conference Paper

References (13)

1. Silberstein SD: Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55: 754-762.
2. 1B/1D agonists) in migraine: Detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002;22:633-658.
3. 1B/1D agonists) in acute migraine treatment: A meta-analysis of 53 trials. Lancet 2001;358:1668-1675.
4. Tfelt-Hansen P, Block G, Dahlöf C, Diener HC, Ferrari MD, Goadsby PJ, Guidetti V, Jones B, Lipton RB, Massiou H, Meinert C, Sandrini G, Steiner T, Winter PB: Guidelines for controlled trials of drugs in migraine: Second edition. Cephalalgia 2000;20:765-786.
5. International Headache society committee on clinical trials in migraine: Guidelines for controlled trials of drugs in migraine; First edition. Cephalalgia 1991;11:1-12.
6. Massiou H, Tzourio C, el Amrani M, Bousser MG: Verbal scales in the acute treatment of migraine: Semantic categories and clinical relevance. Cephalalgia 1997;17:37-39; discussion 32.
7. Lipton RB, Stewart WF: Acute migraine therapy: Do doctors understand what patients with migraine want from therapy? Headache 1999; 39(suppl 2):S20-S26.
8. Davies GM, Santanello N, Lipton R: Determinants of patient satisfaction with migraine therapy. Cephalalgia 2000;20:554-560.
9. Santanello NC, Davies G, Allen C, Kramer M, Lipton R: Determinants of migraine-specific quality of life. Cephalalgia 2002;22:680-685.
10. Gallagher RM, Kunkel R: Migraine medication attributes important for patient compliance: Concerns about side effects may delay treatment. Headache 2003;43:36-44.
11. Williams P, Reeder CE: A comparison of the cost-effectiveness of almotriptan and sumatriptan in the treatment of acute migraine using a composite efficacy/tolerability end point. J Manag Care Pharm 2004;10:259-265.
12. Williams P, Reeder CE: Cost-effectiveness of almotriptan and rizatriptan in the treatment of acute migraine. Clin Ther 2003;25:2903-2919.
13. Dodick D, Martin V: Triptans and CNS side-effects: Pharmacokinetic and metabolic mechanisms. Cephalalgia 2004;24:417-424.